| FDA Office of Minority Health and Health Equity July 29, 2022 Today, the U.S. Food and Drug Administration is providing an update on its multipronged response to monkeypox in the United States, including its efforts in the areas of diagnostics, vaccines and therapeutics. The agency has also established a dedicated website to provide important information about the FDA's ongoing regulatory activities related to monkeypox along with frequently asked questions. The FDA will provide updates as developments occur and will continue to work with federal public health partners and industry to ensure timely access to all available medical countermeasures. "The FDA has been closely tracking reports of monkeypox transmissions in the United States with our federal public health partners and coordinating preparedness efforts accordingly," said FDA Commissioner Robert M. Califf, M.D. "We understand that while we are still living with COVID-19, an emerging disease may leave people feeling concerned and uncertain, but it's important to note that we already have medical products in place, specifically an FDA-approved vaccine for the prevention of monkeypox disease and an FDA-cleared diagnostic test. The FDA is using the full breadth of its authorities to make additional diagnostics and treatments available. We will continue to collaborate with our partners across all sectors to expand accessibility to countermeasures and bolster the tools in our arsenal as appropriate." Visit the FDA OMHHE website and follow us on Twitter at @FDAHealthEquity
"Creating a world where health equity is a reality for all."
www.fda.gov/HealthEquity  | | | |
No comments:
Post a Comment